Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1765-1772

  Datar, R ^a   Kaesemeyer, W H ^a   Chandra, S ^a   Fulton, D J ^a   Caldwell, R W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

calcium; endothelial cells; eNOS; lovastatin; nitric oxide; phospholipase C; pravastatin; scavenger receptor B1

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; BRADYKININ B2 RECEPTOR; CHELATING AGENT; CHOLERA TOXIN; CHOLESTEROL; EGTAZIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE SYNTHASE; PERTUSSIS TOXIN; PHOSPHOLIPASE C; PRAVASTATIN; SCAVENGER RECEPTOR BI;

ANIMAL CELL; AORTA; ARTICLE; CALCIUM TRANSPORT; CELL STRAIN COS7; CONTROLLED STUDY; COW; ENDOTHELIUM; ENZYME ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; BLOTTING, WESTERN; CALCIUM; CATTLE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUMINESCENT MEASUREMENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SCAVENGER RECEPTORS, CLASS B; TRANSFECTION; TYPE C PHOSPHOLIPASES;

EID: 77954347313     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00817.x     Document Type: Article

References (40)

1. Assanasen C, Mineo C, Seetharam D, Yuhanna IS, Marcel YL, Connelly MA et al. (2005). Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest 115:969 977.
2. Auer J, Berent R, Eber B (2001). Lessons learned from statin trials. Clin Cardiol 24:277 280.
3. Church JE, Fulton D (2006). Differences in eNOS activity because of subcellular localization are dictated by phosphorylation state rather than the local calcium environment. J Biol Chem 281:1477 1488.
4. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A et al. (2001). Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 51:283 293.
5. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A (2009). Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54:558 565.
6. Dupuis J, Tardif JC, Cernacek P, Theroux P (1999). Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99:3227 3233.
7. Faggiotto A, Paoletti R (2000). Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? Curr Atheroscler Rep 2:20 25.
8. Farmer JA (2000). Pleiotropic effects of statins. Curr Atheroscler Rep 2:208 217.
9. Fonarow GC (2002). Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients? Curr Atheroscler Rep 4:99 106.
10. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597 601.
11. Group SSSS (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383 1389.
12. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ et al. (2004). Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287:H560 H566.
13. Hou C, Kirchner T, Singer M, Matheis M, Argentieri D, Cavender D (2004). In vivo activity of a phospholipase C inhibitor, 1-(6-((17beta-3-methoxyestra-1, 3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122), in acute and chronic inflammatory reactions. J Pharmacol Exp Ther 309:697 704.
14. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S et al. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67:863 876.
15. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW (1999). Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33:234 241.
16. Keef KD, Hume JR, Zhong J (2001). Regulation of cardiac and smooth muscle Ca(2+) channels (Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol 281:C1743 C1756.
17. Kielczewski JL, Jarajapu YP, McFarland EL, Cai J, Afzal A, Calzi SL et al. (2009). Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 105:897 905.
18. Kitayama K, Nishizawa T, Abe K, Wakabayashi K, Oda T, Inaba T et al. (2006). Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice. J Pharm Pharmacol 58:1629 1638.
19. Koh KK (2000). Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648 657.
20. Krieger M (2001). Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108:793 797.
21. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004 1010.
22. Lampiao F, Strijdom H, Plessis SS (2006). Direct nitric oxide measurement in human spermatozoa: flow cytometric analysis using the fluorescent probe, diaminofluorescein. Int J Androl 29:564 567.
23. Laufs U, La Fata V, Plutzky J, Liao JK (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129 1135.
24. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ (1999). Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100:178 184.
25. Liao JK, Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89 118.
26. Noor R, Shuaib U, Wang CX, Todd K, Ghani U, Schwindt B et al. (2007). High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 192:92 99.
27. Peng Y, Akmentin W, Connelly MA, Lund-Katz S, Phillips MC, Williams DL (2004). Scavenger receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasma membrane domain is a way station for cholesterol trafficking between cells and high-density lipoprotein. Mol Biol Cell 15:384 396.
28. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F et al. (1992). Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 32:136 140.
29. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AF et al. (2003). Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107:1848 1851.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195 2207.
31. Sterin-Borda L, Gomez RM, Borda E (2002). Role of nitric oxide/cyclic GMP in myocardial adenosine A1 receptor-inotropic response. Br J Pharmacol 135:444 450.
32. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y et al. (2006). Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114:2655 2662.
33. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ (2000). High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275:11278 11283.
34. Venema RC, Sayegh HS, Kent JD, Harrison DG (1996). Identification, characterization, and comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide synthases. J Biol Chem 271:6435 6440.
35. Wang JP (1996). U-73122, an aminosteroid phospholipase C inhibitor, may also block Ca2+ influx through phospholipase C-independent mechanism in neutrophil activation. Naunyn Schmiedebergs Arch Pharmacol 353:599 605.
36. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G (2003). Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93:e98 e103.
37. Waters DD (2006). What the statin trials have taught us. Am J Cardiol 98:129 134.
38. Wilde JI, Watson SP (2001). Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal 13:691 701.
39. Yamada M, Huang Z, Dalkara T, Endres M, Laufs U, Waeber C et al. (2000). Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab 20:709 717.
40. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P et al. (2001). High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7:853 857.